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Abstract
Introduction The status of the gene encoding human EGF-like
receptor 2 (HER2) is an important prognostic and predictive
marker in breast cancer. Only breast cancers with HER2
amplification respond to the targeted therapy with trastuzumab.
It is controversial to what degree the primary tumour is
representative of distant metastases in terms of HER2 status.
Discrepancies in HER2 status between primary tumours and
distant metastases have been described, but their reasons
remain unclear. Here, we compared HER2 status on cytological
specimens of distant metastases with the result from the primary
carcinomas, and explored the prevalence of and the reasons for
discrepant results.
Methods HER2 status was determined by fluorescence in situ
hybridisation. HER2 gene amplification was defined as a HER2/
chromosome 17 signal ratio of 2 or more. HER2 results from
cytological specimens of matched distant metastases were
compared with the results from the corresponding primary
tumours (n = 105 patients). In addition, lymph node metastases
were analysed in 31 of these patients.
Results  HER2  amplification was found in 20% of distant
metastases. HER2 status was discordant between the primary
tumour and distant metastasis in 7.6% of the 105 patients. Re-
evaluation revealed that in five patients (4.7%), discrepancies
were due to interpretational difficulties. In two of these patients,
focal amplification had initially been overlooked as a result of
heterogeneity in the primary tumours or in the metastases,
respectively. A further three patients had borderline
amplification with a ratio close to 2. Discrepancy remained
unexplained in three patients (2.9%).
Conclusion HER2 gene status remains highly conserved as
breast cancers metastasise. However, discrepant results do
occur because of interpretational difficulties and heterogeneity
of  HER2  amplification. Cytological specimens from distant
metastases are well suited for HER2  fluorescence  in situ
hybridisation analysis.
Introduction
The  HER2  oncogene encodes a transmembrane tyrosine
kinase (human EGF-like receptor 2) located on chromosome
17q21 [1,2]. HER2 protein belongs to the epidermal growth
factor family [3] and is important for cell differentiation, adhe-
sion and motility [4]. HER2 gene amplification and protein
overexpression exists in about 20% of breast cancers [5,6]
and is linked to a poor prognosis [7]. From a clinical point of
view, HER2 receptor has become important as a target for
antibody-based therapy with trastuzumab (Herceptin®) [8].
Trastuzumab was originally approved for the treatment of met-
astatic HER2-positive breast cancers because of a significant
survival benefit when given in combination with paclitaxel [9-
11]. More recently, adjuvant treatment of primary, HER2-posi-
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isation; HER2 = gene encoding human EGF-like receptor 2; SSC = saline sodium citrate; TMA = tissue microarray.Breast Cancer Research    Vol 9 No 3    Tapia et al.
Page 2 of 8
(page number not for citation purposes)
tive breast cancers with trastuzumab has been shown to
improve patient outcome markedly [12]. Thus, determination
of HER2 status in every breast cancer patient to select for
adjuvant treatment with trastuzumab is becoming a standard
worldwide. There has been much debate on how to test HER2
status. Other than fluorescence in situ hybridisation (FISH),
immunohistochemistry is liable to technical and interpreta-
tional variability [13-15]. Accordingly, it has been shown that
response to trastuzumab is strongly associated with HER2
gene status irrespective of protein expression determined by
immunohistochemistry [16,17]. Importantly, no standardised
immunocytochemical assay is available for cytological speci-
mens. For these reasons, testing the HER2 gene status by
FISH is now widely regarded as the gold standard [18].
HER2 status is commonly determined in the primary tumour,
because biopsies from metastasised lesions are not always
available. In three previous FISH studies on 12 to 68 patients,
the prevalence of a discrepant result between the primary
breast cancer and the distant metastasis ranged from 0% to
22.2% [19-23].
Because of the controversial data and the therapeutic impor-
tance of HER2 testing, we compared the HER2 status in a
large series of primary breast cancers and their matched dis-
tant metastases by FISH. In addition, we attempted to eluci-
date reasons for these discrepancies.
Our results demonstrate that discrepancies in HER2 gene sta-
tus between primary breast cancers and matched metastases
do occur and may be related to technical and interpretational
difficulties.
Materials and methods
Patients and specimens
A consecutive series of 105 cytological specimens from dis-
tant metastases of breast cancer samples was obtained from
the institute for Pathology of the University Hospital Basel (n =
92), the Cantonal Institute for Pathology in Liestal (n = 7) and
the Cantonal Institute for Pathology in St Gallen (n = 6), Swit-
zerland. The specimens had been collected between the years
1999 and 2006. Data on pT (tumour size and invasion) and pN
(lymph-node status) categories were obtained from the origi-
nal pathology reports. Because systematic histological grad-
ing according to Bloom Richardson Elston [24] was not
available in all patients, we used the nuclear grade (1 to 3) that
was described in all cases. A tissue block containing repre-
sentative tissue from each of the primary breast cancers was
retrieved from the archives of the above-listed institutes as well
as from Viollier AG, Division of Histopathology, Basel. A tissue
microarray (TMA) was constructed from these original blocks
as described previously [25]. The TMA included 87 primary
breast cancers and 38 matched lymph node metastases that
had not been previously analysed by FISH. One tissue core
with a diameter of 0.6 mm was sampled from each of the pri-
mary tumours. Because lymph node metastases can be
missed on the TMA cores as a result of focal distribution we
sampled three TMA cores of each positive lymph node. Eleven
primary tumours and seven lymph nodes had no informative
results on the TMA because of missing tissue, no tumour tis-
sue or unsuccessful hybridisation. In these cases we analysed
a routine tissue sections of the primary tumour by FISH.
Whole-tissue section analysis was performed in a further six
tumours that were not represented on the TMA. In a further 12
primary tumours, FISH results were already available from pre-
vious analyses that had been performed in the diagnostic set-
ting. The characteristics of all 105 patients and their primary
tumour are summarised in Table 1. The sites of the metastases
are shown in Table 2. The median time between breast cancer
diagnosis and the cytological diagnosis of the distant metas-
tases was 66 months (range 0 to 254 months). Eight patients
had synchronous metastases (interval less than 1 month).
Information on the treatment between the resection of the pri-
mary tumour and the occurrence of distant metastases was
not available in this study. However, standard adjuvant treat-
ment was performed in accordance with the guidelines of the
consensus conference of St Gallen, 2005 [26]. None of the
patients with discrepant HER2 results received trastuzumab
therapy.
Table 1
Characteristics of patients and their primary breast cancers
Characteristic n (percentage)
Age (years)
Mean 57.5
Range 26–85
Tumour size (cm)
≤ 22 8  ( 2 6 . 6 )
>2 ≤ 55 7  ( 5 4 . 3 )
>5 9 (8.6)
Not available 11 (10.5)
Histological type
Ductal 82 (78.1)
Lobular 12 (11.4)
Ductulo-lobular 10 (9.5)
Medullary 1 (1)
Nuclear grade
17  ( 6 . 7 )
24 1  ( 3 9 )
35 5  ( 5 2 . 4 )
Not available 2 (1.9)Available online http://breast-cancer-research.com/content/9/3/R31
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Specimen pretreatment and FISH assay
For FISH analysis of the cytological specimens, the most rep-
resentative routine Papanicolaou-stained smears or cytospins
were used. A hybridisation target area of 22 mm × 22 mm was
selected on the basis of high cellularity. This area was first
marked with a waterproof pen. In rare tumour cells, the exact
locations of the tumour cells in this marked area were saved
with relocalisation software (Mark&Find Module; Carl Zeiss
Vision GmbH, Halbermoos, Germany) linked to an automated
stage (type 00-24-473-0000; Carl Zeiss AG, Oberkochen
Germany) on a Zeiss Axioplan 2 epifluorescence microscope
(Zeiss, Jena, Germany) before hybridisation. We used this sys-
tem to relocate the tumour cells after hybridisation in 34 cases
(32.4%). The commercially available dual-colour FISH probe
PathVysion®  was from Abbott/Vysis (Downers Grove, IL,
USA). The probes were provided at no charge for those
patients in whom FISH analysis was done for research pur-
pose only. It included fluorescence-labelled DNA probes for
the HER2 gene locus (SpectrumOrange) and centromere 17
(CEP17, SpectrumGreen).
FISH was performed, with small modifications, as recom-
mended by the manufacturer. The smears were washed briefly
in xylene until the coverslip could be removed. After that they
were washed in fresh xylene twice, 5 minutes per wash. Then
they were immersed twice in 100% ethanol for 5 minutes and
soaked in 2 × saline sodium citrate (SSC) buffer for 1 minute
at room temperature (20–24°C). Subsequently they were
incubated in 0.5 mg/ml pepsin solution in 10 mM hydrochloric
acid for 10 minutes at 37°C, followed by a wash in phosphate-
buffered saline for 5 minutes. The smears were washed twice
in Carnoy's fixative for 5 minutes, each time at room tempera-
ture, and dehydrated by immersion in 70% ethanol solution for
5 minutes, also at room temperature, followed by immersion in
80% and 100% ethanol. After that the slides were denatured
for 10 minutes in 70% formamide/2 × SSC at 73°C. Finally,
the smears were dehydrated in a series of 70%, 85% and
100% ethanol (2 minutes per solution), then dried in an oven
at 37 to 45°C for 2 minutes.
After denaturation at 73°C for 5 minutes, the probe hybridisa-
tion mix was applied to the smears. The smears were then
covered with coverslip (22 mm × 22 mm), sealed with rubber
cement and incubated overnight in a humid chamber at 37°C.
Next morning, the slides were washed in 0.4 × SSC/0.3%
Nonidet P40 at 73°C for 2 minutes. Finally, they were rinsed
twice in 2 × SSC/0.1% Nonidet P40 for 2 minutes and then
air-dried. 4',6-Diamidino-2-phenylindole (DAPI II) was added
for counterstaining.
FISH on the histological specimens of the primary tumours
was performed as described previously [17]. We analysed the
slides with a Zeiss Axioplan 2 epifluorescence microscope
(Zeiss, Jena, Germany) equipped with filter sets for DAPI,
SpectrumOrange and SpectrumGreen at a magnification of
×1,000. HER2 amplification was defined as a HER2/CEP17
ratio of 2.0 or more. The number of signals and the HER2/
CEP17 ratio were first estimated on the tissue specimens of
the TMA. The tumours that had an apparently normal ratio and
those with an unequivocal amplification (dense clusters of
HER2 signals or an estimated ratio of more than 2.5) were not
analysed again. In the cytological specimens, the ratio was cal-
culated on the basis of 60 scored cells in most cases. In 14
(13%) of the cytological specimens fewer than 60 tumour
cells were available for FISH analysis (range 6 to 59 cells).
Cases with a discrepant HER2 result between the primary
tumour and the metastases were scored again, and at least 20
cells were counted for confirmation. In addition, a routine tis-
sue section of the original donor block was analysed by FISH
in discrepant cases in which the primary tumour was repre-
sented on the tissue microarray. Thus, a possible sampling
bias due to the small size of the TMA cores could be excluded.
Statistical analysis
The rate of concordance between the primary tumour and met-
astatic tumour was analysed with the kappa coefficient (κ). A
value of κ > 0.8 suggests an 'excellent' concordance in ampli-
fication status between the two tumour sites, whereas a κ
value between 0.61 and 0.8 indicates 'substantial' agreement.
Contingency table analysis was applied to calculate the asso-
ciation between pT category, pN category, nuclear grade and
HER2 FISH status. Analysis of variance (ANOVA) or Student's
t test was applied to determine the parameters with greatest
influence on the time to metastasis. The level of statistical sig-
nificance was set at p ≤ 0.05 two-sided), and all statistical cal-
culations were performed with JMP 3.0 software (SAS
Institute Inc., Cary, NC, USA).
Results
The  HER2  status of the primary breast cancers and the
matched metastases was concordant in 92.4% of the 105
Table 2
Localisation of the metastases
Localisation n Percentage
Ascites 3 2.8
Liver 4 3.8
Lung 9 8.6
Distant lymph nodes 3 2.9
Pericardium 1 1.0
Pleura 74 70.5
Skin/soft tissue 3 2.8
Central nervous system 8 7.6
Total 105 100Breast Cancer Research    Vol 9 No 3    Tapia et al.
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patients at the time of the initial evaluation (κ = 0.76; 95% con-
fidence interval (CI) 0.61 to 0.92). This substantial concord-
ance was increased to 97.1% after re-evaluation of all
discordant cases (κ = 0.85; 95% CI = 0.73 to 0.98).
HER2 amplification was found in 22 (21%) of the 105 primary
tumours and in 21 (20%) of the matched distant metastases.
The HER2 status between primary tumours and distant metas-
tases differed in eight (7.6%) of the patients at the time of the
initial evaluation.
The primary tumours of all eight discrepant cases were reana-
lysed on routine tissue sections, and the hybridised cytological
specimens were carefully scored again. On the routine tissue
sections we calculated an exact ratio from at least 20 scored
cells. The clinicopathological characteristics and FISH find-
ings of these patients are summarised in Table 3.
Re-evaluation showed that in one patient with HER2 amplifica-
tion of the primary tumour, rare tumour cells with HER2 ampli-
fication in the pleural effusion had been overlooked as a result
of rarity of malignant cells and a highly predominating back-
ground of reactive mesothelial cells and macrophages (Figure
1a,b). In another patient, tumour cells in the pleural effusion
but not on the TMA specimen of the primary tumour showed
HER2 amplification. However, FISH on the routine tissue sec-
tion of the primary tumour revealed a heterogeneous HER2
status with only a few amplified tumour cells (Figure 1c,d).
In another patient, metastasis showed low-level gain but no
amplification of the HER2  gene (HER2/CEP17  ratio 1.25,
with 3 to 10/4 to 6 signals), whereas the primary tumour had
initially been scored as amplified on the TMA spot. Routine
section FISH analysis of the primary tumour also revealed low-
level gain with a HER2/CEP17 ratio of 1.6 (with 1 to 2/2 to 6
signals). A further two patients had a 'borderline' amplification.
One patient had an average HER2/CEP17 ratio of 2.1 (with 3
to 9/2 to 4 signals) in the primary tumour but a ratio of only
1.38 in the metastasised cells of the peritoneal effusion (with
3 to 23/3 to 15 signals). The other patient had a HER2/
CEP17 ratio of 2.1, with 2 to 8/2 signals after repeated count-
ing of 20 tumour cells, whereas the metastatic cells had a ratio
of 1.69 (5 to 10/3 to 6 signals).
Three patients (2.9%) remained with an unexplained discrep-
ancy even after re-evaluation of the cytological specimens and
repeated FISH analysis of the routine tissue sections of the pri-
mary tumour (Figure 1e,f). Two of the patients had a primary
tumour with a normal copy number of HER2 and chromosome
17 but with HER2 amplification in the metastasis. The other
patient had high-level amplification with a ratio of more than 3
in the primary tumour (10 to 20/2 to 4), in contrast with a ratio
of 1.83 (3 to 6/2 to 3) in the metastasis.
HER2 amplification was significantly associated with nuclear
grade but not with pT and pN category (Table 4). Time from
resection of the primary tumour to the diagnosis of metastases
was not significantly associated with the pT category (p =
0.248), the pN category (p = 0.1383) or the nuclear grade (p
= 0.3777; detailed data not shown). Metastases tended to
occur earlier in tumours with HER2 amplification than in those
without (44.1 ± SEM 7.8 months versus 71.8.6 ± SEM 7.3
months; p = 0.0639).
The whole metastatic cascade from primary tumour to axillary
lymph node metastasis and distant metastasis was analysed in
31 patients (29.5%). One patient with discordant HER2 sta-
tus between the primary tumour (HER2/CEP17 ratio 2.1) and
Table 3
Clinicopathological characteristics and discrepant HER2 FISH status between primary tumour and distant metastasis
Case no. Age (years) Clinicopathological characteristics HER2 status
Tumour size (cm) Histology Gradea Metastatic Metastases Primary tumour Explanationb
1 34 1.0 Ductal 3 Pleura Amplified Negative True discrepancy
2 52 Not available Ductal 3 Cerebrospinal fluid Amplified Negative True discrepancy
3 65 2.5 Ductal 3 Pleura Amplified Negative True amplification
4 52 1.6 Ductal 3 Pleura Negative Amplified True amplification
5 47 1.8 Ductal 3 Ascites Negative Amplified Borderline
6 47 Not available Ductal 3 Pleura Negative Amplified True amplification
7 82 5.2 Ductal 2 Pleura Negative Amplified Borderline
8 62 2.5 Ductal 3 Lung Negative Amplified True negative
HER2, gene encoding human EGF-like receptor 2; FISH, fluorescence in situ hybridization; true discrepancy, discrepancy remained unexplained; 
true amplification, amplification was found both in the metastasis and in the primary tumour after review; true negative, amplification was not 
confirmed after review; borderline, discrepancy was explained by interpretational difficulty due to a HER2/CEP17 ratio close to the threshold of 2 
or less. aNuclear grade (1 to 3); bexplanations for the discrepancies of HER2 status.Available online http://breast-cancer-research.com/content/9/3/R31
Page 5 of 8
(page number not for citation purposes)
the distant metastasis (HER2/CEP17 ratio 1.38) had a 'bor-
derline result' in the lymph node (HER2/CEP17 ratio 1.9).
There was complete concordance of the FISH results in the
remaining 30 cases, 4 of which showed amplification.
Discussion
HER2  amplification identifies patients who are likely to
respond to therapy with trastuzumab, a humanised antibody
directed against the HER2 protein [27,28]. Approval of trastu-
zumab was originally restricted to patients with HER2-positive
metastatic disease. On the basis of the positive results of
recent international trials [12], approval is now being extended
internationally to adjuvant treatment of HER2-positive breast
cancers. In the mean time, HER2 analysis of all newly diag-
nosed breast cancers has already become a standard in many
institutions. Because of the high costs of trastuzumab and the
risk of cardiotoxicity in some patients [29], it is crucial to make
a precise selection of patients for treatment to guarantee opti-
mal clinical benefit while retaining cost effectiveness.
In patients with metastatic disease, selection for therapy with
trastuzumab has traditionally been based on the HER2 status
of the primary tumour. The reported prevalence of discordance
of  HER2  status between primary tumour and metastasis
ranges from 0 to 22.2% when assessment with both immuno-
histochemistry and FISH is considered [20,21,23,30]. Part of
these discrepancies is likely to be due to the well-known tech-
nical and interpretational limitations of immunohistochemical
HER2 assessment [13,15,31]. Because FISH is considered
the gold standard for HER2 testing [32,33], we investigated
the discordance rate based solely on FISH in a large consec-
utive series of metastatic breast cancers. We found a discrep-
ancy in 8 (7.6%) of the 105 patients. This is in the range of
previous studies with FISH and confirms considerable stability
of HER2 gene status even in tumours that developed distant
metastases more than 21 years after initial surgery (Table 5)
[19,21]. The discrepancies included three tumours with
positive primaries but negative metastases, as determined by
FISH, and five positive metastases but negative primaries.
There would therefore be a risk of both undertreatment and
overtreatment of these metastasised breast cancers if the
treatment decision were based only on the HER2 status of
these primary tumours.
The reasons for discrepancy in HER2 FISH status between
primary breast cancer and metastases have not been
investigated in previous studies. Here, detailed re-evaluation
of the HER2 FISH status by scoring the specimens again or
by hybridising routine tissue sections allowed us to discover
reasons for HER2 discrepancies. Not all discrepant results
represented true biological conversion. Instead, we uncovered
interpretational difficulties as a reason in five (4.7%) of the
patients. One had a slight gain of HER2  signals that was
regarded as amplified in the first evaluation. In two patients,
the discrepancy was explained by a HER2/reference ratio that
was slightly lower or higher than the threshold of 2, which we
refer to as 'borderline'. It is conceivable that such a borderline
ratio is more prone to inter-observer variation than amplifica-
tion with a high ratio or dense gene clusters. In a recent inter-
laboratory survey, there was a considerable variability in inter-
pretation of cases with low-level or borderline amplification
[34]. In contrast, those authors found excellent reproducibility
in HER2 FISH analysis for tumours with no amplification or
high amplification of the HER2 gene. This highlights the need
for consensus on the use of an equivocal/borderline interpre-
tative category. Accordingly, the package insert of the PathVy-
sion includes the statement 'a ratio at or near the cutoff (1.8 to
2.2) should be interpreted with caution'. The clinical relevance
of this type of interpretational limitation is not clear, because
the impact of the ratio level on the likelihood of therapy
response is still unknown. One could hypothesise that the
Figure 1
Examples of discrepancies of HER2 FISH status between primary  breast cancers and matched distant metastases Examples of discrepancies of HER2 FISH status between primary 
breast cancers and matched distant metastases. HER2 (gene encod-
ing human EGF-like receptor 2) fluorescence in situ hybridisation 
(FISH) status on histological specimens (a, c, e) and matched cytolo-
gies of distant metastases (b, d, f). (a, b) Discrepancy due to interpreta-
tional difficulty. High-level amplification in primary tumour (a), and rare 
amplified metastatic cells in pleura effusion that had been overlooked 
(b). (c, d) Discrepancy due to heterogeneity. Rare tumour cells (arrow) 
with amplification in the primary breast cancer (c), and metastatic cells 
in pleural effusion with amplification (d). (e, f) True discrepancy. HER2-
negative primary breast cancer (e), and amplification in metastatic cells 
(f). Original magnifications ×630 to 1,000.Breast Cancer Research    Vol 9 No 3    Tapia et al.
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response rate is low in breast cancers with a borderline FISH
result.
Rarity of HER2 amplified cells was responsible for a discrep-
ancy in a further two patients. In one of these, rare HER2-
amplified cells were initially overlooked on a cytological smear
from metastasis with a high background of reactive cells. In the
other patient, rare amplified cells were not detected initially
because of intratumoral heterogeneity of HER2 status within
the primary tumour. In this patient, we must assume the pres-
ence of clonal selection of the rare HER2-amplified cells in the
primary for distant metastatic spread. Our finding also empha-
sises the importance of careful and thorough evaluation of the
hybridised specimens, because heterogeneity with small can-
cer foci prevails in rare cases [35,36].
In three of the eight patients (patients 1, 2, and 8 in Table 3)
we could not identify any interpretational reason for the dis-
crepancy. Two of these were negative, as determined by FISH,
in the primary but positive in the metastasis. In the third
tumour, high-level amplification in the primary contrasted with
low-level gain in the metastasis. It is possible that these three
tumours represented true conversion of HER2 status by clonal
selection or genetic drift during metastatic progression. How-
ever, we cannot exclude the possibility of undetected hetero-
geneity even in these cases, because only a small percentage
of the entire tumour volume is represented on a histological
section or on a cytological smear [37,38].
The patients of this study were selected on the basis of the
availability of cytologically diagnosed distant metastases. Fine-
needle aspiration cytology of solid lesions or exfoliative cytol-
ogy (for example malignant effusions) is a commonly used
method to diagnose or confirm metastatic disease. Our results
confirm that cytological specimens are well suited to HER2
FISH analysis [22,39,40]. It has previously been shown that
results of HER2 FISH analyses from cytological specimens
are highly concordant with matched histological sections
[41,42]. It is therefore unlikely that our results were affected by
the different types of tumour material of primary tumours and
metastases.
The standard morphological parameters (pT category, pN cat-
egory and grade) are strong prognostic factors in newly diag-
nosed breast cancer [43]. Interestingly, none of these
parameters was significantly associated with the time interval
Table 4
Comparison between HER2 amplified and non-amplified primary breast cancers
Characteristic n amplified (percentage) n not amplified (percentage) p
pT category
pT1 3 (10.3) 26 (89.7) 0.31
pT2 13 (26.5) 36 (73.5)
pT3 2 (28.6) 5 (71.4)
pT4 2 (14.3) 12 (85.7)
Not available 2 (33.3) 4 (66.7)
Nodal status
Positive 14 (21.9) 50 (78.1) 0.44
Negative 4 (14.8) 23 (85.2)
Not available 4 (28.6) 10 (71.4)
Histologal type
Ductal 20 (24.4) 62 (75.6) 0.30
Lobular 2 (16.7) 10 (83.3)
Ductulo-lobular 0 10 (100)
Medullary 0 1(100)
Nuclear grade
10 7  ( 1 0 0 ) 0 . 0 1
2 4 (9.8) 37 (90.2)
3 18 (32.7) 37 (67.3)
Not available 0 2 (100)
HER2, gene encoding human EGF-like receptor 2.Available online http://breast-cancer-research.com/content/9/3/R31
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from initial treatment to cytological diagnosis of distant metas-
tasis in our selected series of patients. Because the time of
cytological sampling of metastatic cells is not always identical
with the time of first clinical detection of metastasis, prognos-
tic data must be interpreted with caution in our study.
Nevertheless, our data indicate that within the group of breast
cancers that are capable of distant metastasis, the dynamics
of metastasis is driven by biological or environmental factors
that are not fully reflected by morphological features. The
observed tendency of HER2  amplification towards early
metastasis is concordant with the known adverse prognostic
role of HER2 amplification [44].
Conclusion
HER2  FISH status is highly preserved as breast cancers
progress to metastatic disease. However, a discrepancy in
HER2 status exists in a small fraction of patients. As well as
true conversion of HER2  status, interpretational difficulties
due to borderline FISH results, rarity of tumour cells and intra-
tumoral heterogeneity were identified as important reasons for
the discrepancy. Irrespective of the reason, however, every
discordance in HER2 status is a diagnostic reality and can
lead to inaccurate treatment decisions with medical and eco-
nomical effects. To guarantee optimal care of individual
patients, we advocate HER2 analysis of distant metastases in
all patients irrespective of the result in the primary tumour. The
feasibility of this approach will ultimately be determined by
economic factors. Future patients with distant metastases
after adjuvant treatment for HER2-positive breast cancer will
pose additional diagnostic and therapeutic challenges. It is
possible that treatment with trastuzumab leads to clonal selec-
tion of HER2-negative tumour cells, as observed in individual
patients [35]. Thus, HER2 testing of metastasis may become
a necessity in every patient.
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